Fast track for blocked blood vessel treatment

The US FDA has granted Fast Track Designation to Israel’s BioGenCell (see here previously) for the development of BGC101 – its lead candidate for treating severe Critical Limb Threatening Ischemia (CLTI).

https://finance.yahoo.com/news/biogencell-receives-fda-fast-track-140000739.html

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *